EA200401345A1 - Лечение гастропареза - Google Patents

Лечение гастропареза

Info

Publication number
EA200401345A1
EA200401345A1 EA200401345A EA200401345A EA200401345A1 EA 200401345 A1 EA200401345 A1 EA 200401345A1 EA 200401345 A EA200401345 A EA 200401345A EA 200401345 A EA200401345 A EA 200401345A EA 200401345 A1 EA200401345 A1 EA 200401345A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
gastroparezes
gastroparesis
patients
glp
Prior art date
Application number
EA200401345A
Other languages
English (en)
Russian (ru)
Inventor
Джозеф Энтони Якубовски
Турман Дуайт Маккинни
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200401345A1 publication Critical patent/EA200401345A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EA200401345A 2002-04-10 2003-03-27 Лечение гастропареза EA200401345A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37165002P 2002-04-10 2002-04-10
PCT/US2003/008457 WO2003087139A2 (en) 2002-04-10 2003-03-27 Treatment of gastroparesis

Publications (1)

Publication Number Publication Date
EA200401345A1 true EA200401345A1 (ru) 2005-08-25

Family

ID=29250714

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401345A EA200401345A1 (ru) 2002-04-10 2003-03-27 Лечение гастропареза

Country Status (18)

Country Link
US (1) US20050164925A1 (https=)
EP (1) EP1496924A4 (https=)
JP (1) JP2005530732A (https=)
KR (1) KR20040098063A (https=)
CN (1) CN1735423A (https=)
AU (1) AU2003220403A1 (https=)
BR (1) BR0308904A (https=)
CA (1) CA2480858A1 (https=)
EA (1) EA200401345A1 (https=)
EC (1) ECSP045345A (https=)
HR (1) HRP20040939A2 (https=)
IL (1) IL164266A0 (https=)
MX (1) MXPA04009929A (https=)
NO (1) NO20044815L (https=)
NZ (1) NZ535684A (https=)
PL (1) PL373658A1 (https=)
WO (1) WO2003087139A2 (https=)
ZA (1) ZA200408111B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
CN1856338B (zh) 2003-07-21 2012-11-14 超治疗有限公司 用于治疗疾病和控制血糖的胃肠方法和装置
BR122019021416A2 (https=) * 2003-09-19 2019-12-21
EP1667724A2 (en) * 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
US8612016B2 (en) 2004-08-18 2013-12-17 Metacure Limited Monitoring, analysis, and regulation of eating habits
EP1868679B1 (en) 2005-02-17 2017-05-03 MetaCure Limited Non-immediate effects of therapy
WO2006087712A2 (en) 2005-02-17 2006-08-24 Metacure N.V. Charger with data transfer capabilities
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
EP1861160B1 (en) * 2005-03-24 2011-11-16 Metacure Limited Wireless leads for gastrointestinal tract applications
US8463404B2 (en) 2005-03-24 2013-06-11 Metacure Limited Electrode assemblies, tools, and methods for gastric wall implantation
EP1890763A4 (en) 2005-06-02 2017-05-03 Metacure Limited Gi lead implantation
US8442841B2 (en) * 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
JP2009534423A (ja) * 2006-04-20 2009-09-24 アムジェン インコーポレイテッド Ｇｌｐ−１化合物
AU2012203915B9 (en) * 2006-04-20 2014-10-09 Amgen Inc. GLP-1 compounds
EP2150308B1 (en) * 2007-05-09 2018-08-08 MetaCure Limited Analysis and regulation of food intake
US8423130B2 (en) * 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
US8642548B2 (en) * 2009-08-07 2014-02-04 Mannkind Corporation Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
MX2012012383A (es) 2010-04-30 2012-11-30 Sanwa Kagaku Kenkyusho Co Peptido para mejorar la bioestabilidad de una sustancia bioactica y sustancia bioactiva que tiene bioestabilidad mejorada.
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Also Published As

Publication number Publication date
CN1735423A (zh) 2006-02-15
WO2003087139A2 (en) 2003-10-23
US20050164925A1 (en) 2005-07-28
BR0308904A (pt) 2005-05-03
CA2480858A1 (en) 2003-10-23
EP1496924A4 (en) 2007-05-30
NO20044815L (no) 2005-01-07
WO2003087139A3 (en) 2004-01-08
KR20040098063A (ko) 2004-11-18
AU2003220403A1 (en) 2003-10-27
PL373658A1 (en) 2005-09-05
IL164266A0 (en) 2005-12-18
ZA200408111B (en) 2005-10-07
JP2005530732A (ja) 2005-10-13
MXPA04009929A (es) 2006-03-10
NZ535684A (en) 2006-03-31
EP1496924A2 (en) 2005-01-19
ECSP045345A (es) 2006-04-19
HRP20040939A2 (en) 2004-12-31

Similar Documents

Publication Publication Date Title
EA200401345A1 (ru) Лечение гастропареза
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
GB0225474D0 (en) Therapeutic agents
ATE384058T1 (de) Thiazolderivate
MY135222A (en) Substituted phenylacetamides and their use as glucokinase activators
EP1490044A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMABLE COMPONENTS
UA84025C2 (en) Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORS
PL374865A1 (en) Treatment of tnf alpha related disorders
MY137757A (en) Therapeutic treatment
DK1583541T3 (da) Forbindelser og fremgangsmåder til at øge neurogenese
GEP20084499B (en) USE OF INTERFERON-ß FOR TREATMENT OF RENAL FAILURE
MY136764A (en) Indole-3-carboxamides as glucokinase (gk) activators
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
PL377164A1 (pl) Pochodne anilinopirazolu przydatne do leczenia cukrzycy
NO20045554L (no) Fremgangsmate for behandling av diabetes
MXPA05009014A (es) Antagonistas del receptor ccr-3.
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
NO984950L (no) Forbindelser med veksthormonfrigj°rende egenskaper
ATE417856T1 (de) Motilidverbindungen
IS2254B (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
GEP20094699B (en) THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING ß-INTERFERON
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.